Sequencing tags patients responding to everolimus; Parkinson's signature could help diagnosis;

> Using whole genome and targeted sequencing, researchers have found a genetic change that could be used to identify cancer patients most likely to respond to everolimus. This technique could be used to find similar markers for other cancer drugs. Article | Abstract

> A Parkinson's disease biomarker signature found using microarrays could be used for earlier diagnosis in patients with atypical symptoms. Abstract

> Markers could distinguish between forms of post kala-azar dermal leishmaniasis (PKDL). Abstract

> Deposits of calcium on blood vessel walls could help tag heart risk. Article

> Leptin, adiponectin and PAI-1 have potential as biomarkers to predict metabolic syndrome in teenagers, a growing problem worldwide. Abstract

> Researchers are still hunting down depression biomarkers, according to Genetic Engineering & Biotechnology News. Article

> Brain scans could tag epilepsy causes and treatments. Press release

And Finally… A new diabetes biosensor could test for glucose in saliva or tears. Article

Suggested Articles

The drug that treats atrial fibrillation, flecainide, has been around since the '80s. Grace Colón, CEO of InCarda, thinks it needs a face-lift.

3M, maker of the ubiquitous Littmann stethoscope brand, has teamed up with Eko to create a new digital version that amplifies sounds and adds AI.

Study data from Medtronic showed more patients reported improvements in their chronic back pain after treatments with the devicemaker’s tiny implant.